After a virtual bootcamp, the TMCx team selected seven startups to move forward in the accelerator. Photo courtesy of TMC

Last year, TMCx, the Texas Medical Center's health tech startup accelerator pivoted to digital programming.

The accelerator revamped its program to allow for an initial Bootcamp stage that would bring in a larger group of startups and then, after the boot camp, the program would move forward with a smaller group through the official acceleration process.

"We hosted 21 companies, representing six countries and 10 states, who each engaged with subject matter experts, clinical leaders, and corporate partners," writes Emily Reiser, senior manager of Innovation Community Engagement at TMC Innovation, in a blog post. "Over half of which ended Bootcamp in advanced discussions with hospitals and/or corporate partners."

Through the bootcamp, TMCx has accepted seven startups into the program. These companies are currently engaged with the TMC community and are receiving support, mentorship, and other opportunities.

Cardiosense

Image via cardiosense.com

Chicago-based Cardiosense, a medical device company with heart health tracking technology, is familiar with Houston innovation. The company won sixth place in the 2020 Rice Business Plan Competition, and the TMC's prize at the event.

Cognetivity Neurosciences

Image via Getty Images

Cognetivity Neurosciences, founded in the United Kingdom, is a digital health platform that taps into neuroscience and artificial intelligence to measure cognitive performance of patients in order to more effectively allow for early detection and management of neurodegenerative disorders.

Eleos Health

Image via eleos.health

Cambridge, Massachusetts-based Eleos Health is focused on helping behavioral health clinicians to optimize their efforts with an all-in-one behavioral health platform. It combines telehealth, measurement-based, and evidence-based care in one holistic solution, and is powered by therapy-specific voice analysis and natural language processing.

Harmonic Bionics

Image via harmonicbionics.com

Harmonic Bionics is one of two Lone Star State companies in the program. The Austin-based robotics startup is working on technology that can help improve upper extremity rehabilitation for patients.

Native Cardio

Photo via Getty Images

Florida-based Native Cardio is tapping into technology to help find a solution to postoperative atrial fibrillation (POAF), which is the most frequent complication after cardiac surgery, occurring in up to 60 percent of patients, according to the company's website. The goal is to help reduce costs, increase accessibility, and improve quality of care.

Progenerative Medical

Image via progenerative.com

Progenerative Medical, based in San Antonio, is working on a clinically-proven reduced pressure therapy to spinal and orthopedic indications to significantly improve clinical outcomes.

RCE Technologies

Image via rce.ai

Atlanta-based RCE Technologies is an artificial intelligence-enabled medical device company that has created a technology that can detect heart attacks early using non-invasive wearables.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.